Bortezomib (PS-341)

製品コードS1013 別名:LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW):384.24

Bortezomib (PS-341)は一種の有効な20Sプロテアソーム阻害剤で、Ki値が0.6nMですが、正常細胞より腫瘍細胞に良好な選択性をもっと表します。

サイズ 価格(税別)  
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(145)

カスタマーフィードバック(22)

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341)は一種の有効な20Sプロテアソーム阻害剤で、Ki値が0.6nMですが、正常細胞より腫瘍細胞に良好な選択性をもっと表します。
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NF7NPXVEgXSxdH;4bYMhSXO|YYm= MYi1NEDPxE1? NILDdng1QCCq MlrYSG1UVw>? MlLjT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> NWDzS2c1OTB2OUm2OFM>
OVCA 429 NH;GR5NHfW6ldHnvckBCe3OjeR?= NWDqWIY3OzByIH7N MkfiOFghcA>? NUfMS5l1TE2VTx?= NEGzWodFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> M4PaNFExQTl7N{[2
RPMI8226 NFLuVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOyNVAxKG6P NYHjOGdvPDhiaB?= NU\v[pI5TE2VTx?= M{K4ZmlEPTB;M{Cgcm0> M2[0e|EyOzB4NEi5
Dox40 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nIVVExOCCwTR?= NX7PVVQ4PDhiaB?= M2rMW2ROW09? NIi3ZnNKSzVyPUSwJI5O NF;Pd20yOTNyNkS4PS=>
MR20 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNFAhdk1? NYfWPIxkPDhiaB?= NYjrbGpITE2VTx?= M4O2XmlEPTB;MkCgcm0> NIX0VZoyOTNyNkS4PS=>
LR5 NHy5VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXlU5duOTByIH7N M1nNTFQ5KGh? NXnxZphOTE2VTx?= MmTlTWM2OD1{MDDuUS=> MmewNVE{ODZ2OEm=
U266 M1XOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPRNVAxKG6P NUHnZVRDPDhiaB?= Mm\5SG1UVw>? NUSwZmltUUN3ME2zJI5O MnLwNVE{ODZ2OEm=
IM-9 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNFAhdk1? M1XZRVQ5KGh? M3LGVGROW09? NHn1[49KSzVyPU[gcm0> MUexNVMxPjR6OR?=
Hs Sultan MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNFAhdk1? NXy2WFhnPDhiaB?= MnfSSG1UVw>? MVzJR|UxRTJyIH7N NHuxc4QyOTNyNkS4PS=>
PAM-LY2 MojoSpVv[3Srb36gRZN{[Xl? MUixNFAhdk1? NGrNbHcyOiCq NUXJ[FBYTE2VTx?= M4rL[2lvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u M4O5OlEyOzVyOUGz
PAM 212 MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzTPIJYOTByIH7N NInTfWU4OiCq NVPRZZZmTE2VTx?= NVXlcJJ7UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MXexNVM2ODlzMx?=
PAM-LY2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWxNFAhdk1? NYrpXZVHPzJiaB?= M3;FZWROW09? NF7pbnBKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Mk[1NVE{PTB7MUO=
B4B8 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjKbnIyODBibl2= NVTSOo5kPzJiaB?= MX3EUXNQ NGPW[JBKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MmDoNVE{PTB7MUO=
B7E3 M2D5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLKNVAxKG6P NH23e2Q4OiCq M1jjSWROW09? Mo[2TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MWmxNVM2ODlzMx?=
UM-SCC-9 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrSNVAxKG6P MlP6O|IhcA>? Mn62SG1UVw>? NGHWe2hKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NUfOOndSOTF|NUC5NVM>
UM-SCC-11B NEfXTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3OeWYyODBibl2= NUfzRoJuPzJiaB?= MUHEUXNQ MWHJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MXyxNVM2ODlzMx?=
H460 NWfEU3RjTnWwY4Tpc44hSXO|YYm= M3\UclExKM7:TR?= MX[yOEBp M1;4NmROW09? MVXJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 M4LoflEzPDl{MUG3
U266 M1n3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\2OFUxOCCwZz;tcC=> M{TUXVQ5KGh? Mmi2SG1UVw>? MXPJcohq[mm2czDj[YxtKGe{b4f0bC=> M2DmZlEzPjNzNkG5
ARH77 NIGxdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLwOVAxKG6pL33s M3\RZlQ5KGh? M2XXSmROW09? MoPlTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NI\Hb3cyOjZ|MU[xPS=>
WAD-1 NH3NcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi2[|Y2ODBibnevcYw> MXm0PEBp MWTEUXNQ NUC5eYFRUW6qaXLpeJMh[2WubDDndo94fGh? NXXwe|BUOTJ4M{G2NVk>
U266/LR7 M4LNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jIeFUxOCCwZz;tcC=> NY\aZ5hzPDhiaB?= MXvEUXNQ MlvTTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MmTPNVI3OzF4MUm=
U266/dox4 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUG1NFAhdmdxbXy= MkK0OFghcA>? MVXEUXNQ NV7jRVFYUW6qaXLpeJMh[2WubDDndo94fGh? MmLBNVI3OzF4MUm=
RPMI8226/LR5 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTLS4htPTByIH7nM41t M3;hblQ5KGh? MofwSG1UVw>? NIr2PYVKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NIDaXGkyOjZ|MU[xPS=>
H460 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HT[FExKM7:TR?= MoLNO|IhcA>? NVrmXJYxTE2VTx?= M4\WNGlEPTB;MUCwJI5O M3uze|EzPjNzNkKw
H358 NH\rdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnQVIFYOTBizszN NF21d|M4OiCq MnW2SG1UVw>? MnzlTWM2OD15MDDuUS=> NF7ZOpMyOjZ|MU[yNC=>
H322 NVnEWnV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljONVAh|ryP M4jhV|czKGh? MkXhSG1UVw>? NXfYW|JKUUN3ME22NlAhdk1? NXnwelVTOTJ4M{G2NlA>
H460 NH;mZ3hHfW6ldHnvckBCe3OjeR?= MUOxNFAhdk1? NF\JbpkzPCCq NFnvdIFFVVOR MoDzTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? MV[xNlY{OTZ{MB?=
LNCap-Pro5 NYnsfmw1TnWwY4Tpc44hSXO|YYm= Ml7MNUDPxE1? MnfsOEBp MnroSG1UVw>? NVzUXmlYW3SjYnnsbZpmeyCyNUO= NYO2W5BDOTR4MUK1N|I>
T29 NVfhfHQ{SXCxcITvd4l{KEG|c3H5 MmjaOVAhdk1? NF;vV2I1QCCqIB?= NWL6S2s6TE2VTx?= NVj6RXcxUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NVXob4c3OTZ5N{ixO|k>
T29Kt1 M1LKVGFxd3C2b4Ppd{BCe3OjeR?= NFGw[YQ2OCCwTR?= NGnHOHc1QCCqIB?= NEDBflhFVVOR M2nPUWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2r1[lE3Pzd6MUe5
HCT116 NH72fXhCeG:ydH;zbZMhSXO|YYm= M2rqVlUxKG6P NIr1enE1QCCqIB?= NFXIWJdFVVOR NVrZdIlIUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWfGdWN{OTZ5N{ixO|k>
HKe-3 NVnnfXMzSXCxcITvd4l{KEG|c3H5 MUK1NEBvVQ>? NVewWohoPDhiaDC= NHnjNWZFVVOR NWTJbWZnUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MWexOlc4QDF5OR?=
NB-1691 NVHN[IpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETPSpQyKM7:TR?= MUO3NkBp NFrvXFZKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iNTW= M2XNU|E4Pjh7Nki0
CHLA-255 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:xJO69VQ>? Mly1O|IhcA>? MYfJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? MUmxO|Y5QTZ6NB?=
SK-N-AS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:xJO69VQ>? MojXO|IhcA>? NHr3fGhKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMUCl NHTpUWkyPzZ6OU[4OC=>
NB-1691 NUXzXG1FTnWwY4Tpc44hSXO|YYm= NYnHTYhMOTBibl2= NHnpdWszPCCq NXnZTpJyW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NXiydWdmOTd4OEm2PFQ>
CHLA-255 Mn\2SpVv[3Srb36gRZN{[Xl? NEXnUlgyOCCwTR?= MX2yOEBp MX3Nc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? MUixO|Y5QTZ6NB?=
RPMI 8226 MoPYSpVv[3Srb36gRZN{[Xl? MYOyNEBvVQ>? MnfKPEBp M4KzTXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NXrmUFRHOTl2M{[wOVA>
MM.1S MoX6SpVv[3Srb36gRZN{[Xl? NHvlR2YzOCCwTR?= M4Lh[FghcA>? Mk\GV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M3TwblE6PDN4MEWw
U266 NE[5[YhHfW6ldHnvckBCe3OjeR?= MU[yNEBvVQ>? Ml\yPEBp NYjOfZZIW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NGDRb4cyQTR|NkC1NC=>
OPM1 NF\qfldHfW6ldHnvckBCe3OjeR?= NXPUbJQ1OjBibl2= NEnFOpQ5KGh? M1[2R3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M4O1Z|E6PDN4MEWw
INA6 NFHt[lBHfW6ldHnvckBCe3OjeR?= MlPSNlAhdk1? MkflPEBp MlfzV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M1zp[|E6PDN4MEWw
OPM2 NYHUXGhmTnWwY4Tpc44hSXO|YYm= NX\FWHVlOjBibl2= MWS4JIg> NV\0XYFFW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? M3rheFE6PDN4MEWw
RPMI 8226 MVLGeY5kfGmxbjDBd5NigQ>? MWGyNEBvVQ>? Mmi4PEBp MVPJcoR2[2W|IFTORUB{gW62aHXzbZM> MXWxPVQ{PjB3MB?=
BaF/3 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDDNVAxKG6P M1rLOlQ5KGh? MlzGTWM2OD14LkKgcm0> NGTMU3MzODNyNU[5Ni=>
BaF/3-p210 M2e5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HBWlExOCCwTR?= NGTDVZU1QCCq MWrJR|UxRTRwNzDuUS=> NXq2UGlMOjB|MEW2PVI>
TCC-S NE\DSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xNFAhdk1? NH32PIM1QCCq NVvRXJNOUUN3ME2yMlghdk1? MkX6NlA{ODV4OUK=
BaF/3 MVfGeY5kfGmxbjDBd5NigQ>? MX[2JI5O M1zPXVQ5KGh? NX;RfHRlUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MWOyNFMxPTZ7Mh?=
BaF/3-p210 MXHGeY5kfGmxbjDBd5NigQ>? MUi2JI5O M3XseFQ5KGh? NXvOWJZkUW6mdXPld{BiKHOuaXfoeEBIOSClZXzsMYN6[2ynIHHydoV{fA>? NUfzbVgyOjB|MEW2PVI>
BaF/3-p210 NX3McVdRTnWwY4Tpc44hSXO|YYm= NEG4doY3KG6P MUmyOEBp MkjCVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? MkDKNlA{ODV4OUK=
Raji MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixJO69VQ>? NFHJ[HczPCCq Moe3VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NYr3PWxyOjFzN{C5PFg>
LCL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxJO69VQ>? NWq0cpE5OjRiaB?= MYDS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NFrmR3gzOTF5MEm4PC=>
LCL-2 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fvTlEh|ryP M2\xN|I1KGh? M{f1[3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NGDYeZEzOTF5MEm4PC=>
BJAB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXMdXhvOSEQvF2= MkjKNlQhcA>? NHT3NIZT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MmPLNlEyPzB7OEi=
SNT-13 M{jZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe5TpEyKM7:TR?= NV3kSY9iOjRiaB?= NIizS2NT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MoDKNlEyPzB7OEi=
SNT-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\wPJUyKM7:TR?= NHTBeGozPCCq MoDSVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MXSyNVE4ODl6OB?=
Jurkat Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzJV3N4OSEQvF2= NVHMRVdsOjRiaB?= MoTmVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NXHpbGpOOjFzN{C5PFg>
KAI-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC4NVAyKM7:TR?= MViyOEBp M{jS[XJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MmHXNlEyPzB7OEi=
SNK-6 NIOybGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSyNUDPxE1? MmO3NlQhcA>? MYPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MVOyNVE4ODl6OB?=
KHYG-1 NIPURlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG4NUDPxE1? M33UW|I1KGh? MVfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MVGyNVE4ODl6OB?=
SNT-16 M{H4fmFxd3C2b4Ppd{BCe3OjeR?= MYSxJO69VQ>? M4XGeVYhcA>? NV;VZ2NXUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHu4PG4zOTF5MEm4PC=>
Jurkat NFLQNYpCeG:ydH;zbZMhSXO|YYm= NYrwc2lGOSEQvF2= NXrzSJlwPiCq NEWx[ZhKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHrROYwzOTF5MEm4PC=>
KAI-3 NVLWUIIySXCxcITvd4l{KEG|c3H5 NHXOdlYyKM7:TR?= NGTTfZQ3KGh? MWrJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NILyXZYzOTF5MEm4PC=>
KHYG-1 MW\BdI9xfG:|aYOgRZN{[Xl? NFTIUIsyKM7:TR?= NHW1VZE3KGh? NH:yZoVKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYX3TZVDOjFzN{C5PFg>
SNT-13 M{m5PGFvfGm4aYLhcEBCe3OjeR?= MUOxJO69VQ>? MXuyOEBp MnPhTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX Mn\wNlEyPzB7OEi=
SNT-16 M1HaOGFvfGm4aYLhcEBCe3OjeR?= MkXWNUDPxE1? M{DMelI1KGh? NVzHZW5lUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M2i1[FIyOTdyOUi4
KAI-3 NG[yXIpCdnSrdnnyZYwhSXO|YYm= NVrBWo5bOSEQvF2= Mo\1NlQhcA>? NFnnVZFKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NWrLdG9rOjFzN{C5PFg>
SNK-6 Mn\nRY51cX[rcnHsJGF{e2G7 Mn6xNUDPxE1? MnjJNlQhcA>? MVvJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MVSyNVE4ODl6OB?=
RAW 264.7 NGPEPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNFAhdk1? NEDFfWk1QCCq M{PQRnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M2PvcFIzPDJ5MUW0
A375 MlrJRZBweHSxc3nzJGF{e2G7 NXL6eY1mOTBibl2= NHjMUYkzPCCq MkfTTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NEj5SokzOzB5OUC4Ny=>
BLM Ml;FRZBweHSxc3nzJGF{e2G7 MVqxNEBvVQ>? MlfZNlQhcA>? NF3sdJhKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2G3T|I{ODd7MEiz
A375 Mk\4RZV1d3CqYXf5JGF{e2G7 MXmxNEBvVQ>? M3PlWFEzKGh? NWrOXItWUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> NVLTZ|kzOjNyN{mwPFM>
BLM MoW2RZV1d3CqYXf5JGF{e2G7 MYCxNEBvVQ>? MnqxNVIhcA>? NEXVRVdKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> M1ThNlI{ODd7MEiz
H1299 MUfBdI9xfG:|aYOgRZN{[Xl? Moj3PFAhdk1? MUiyOEBp NHr2THFFVVOR NV\qV2RrW2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= MnGxNlU{OjN4OUO=
Hut-78 NYDpeXhOTnWwY4Tpc44hSXO|YYm= NXLVeGtsOTByIH7N NHT0dHozPCCq MorNSG1UVw>? M{PWb2Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= NY[1OJRMOjV4OEGzN|U>
H9 MmK0SpVv[3Srb36gRZN{[Xl? MWmxNFAhdk1? M3PWVlI1KGh? MYjEUXNQ M3T5[mRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= NILB[JAzPTZ6MUOzOS=>
HH M4XnTGZ2dmO2aX;uJGF{e2G7 MXyxNFAhdk1? M{G4blI1KGh? M{LsTGROW09? NXr1THV5\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u MlqxNlU3QDF|M{W=
Hut-78 MnfsUYloemG2aX;uJGF{e2G7 Mlm0NVAxKG6P MYKyOEBp NH\GTJdFVVOR M2L5OXJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= MkDsNlU3QDF|M{W=
HH NVvOc29GVWmpcnH0bY9vKEG|c3H5 NYnvWYlnOTByIH7N MVSyOEBp NIjxZYpFVVOR NGW3[o5T\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl NVHyW4hoOjV4OEGzN|U>
U937 MmrqSpVv[3Srb36gRZN{[Xl? MUixNFAhdk1? MnzvOkBp MV;JcoR2[2W|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{ MnTsNlU4QTF2N{e=
human PBMC NUPtNGM3TnWwY4Tpc44hSXO|YYm= NVmxWpB4OTByIH7N MnzJNlQhcA>? Ml\JTY5lfWOnczDJUE05KHKnbHXhd4U> NV3VfIVKOjV5OUG0O|c>
ES6 NWDD[WJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ftR2lEPTB;MD6wNFIyKG6P NWfUcYhLW0GQR1XS
SK-UT-1 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMU[zJI5O NFfrV5NUSU6JRWK=
SH-4 NWO4[WZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMUezJI5O MWHTRW5ITVJ?
TE-9 M3LwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XrTWlEPTB;MD6xPFIhdk1? NHm3eVZUSU6JRWK=
A253 NVXSe|VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLvTWM2OD1yLkKwPEBvVQ>? MXjTRW5ITVJ?
no-10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHa[4pUUUN3ME2wMlIyKG6P NXrVbZFFW0GQR1XS
MMAC-SF MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLxSYx2UUN3ME2wMlIyPiCwTR?= NXK2dphRW0GQR1XS
A101D NXrBOlRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjMemROUUN3ME2wMlIzPSCwTR?= MWHTRW5ITVJ?
NTERA-S-cl-D1 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrMd5hUUUN3ME2wMlI1OyCwTR?= NX3EOHFqW0GQR1XS
8-MG-BA NUj6V2JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDNTWM2OD1yLkK1JI5O M3LicHNCVkeHUh?=
KNS-42 M4P6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL2bHNKSzVyPUCuNlU5KG6P NF\YPWdUSU6JRWK=
LXF-289 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;JTWM2OD1yLkK2PUBvVQ>? MUTTRW5ITVJ?
OVCAR-4 NXezTHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3flXmlEPTB;MD6yPFkhdk1? MoTNV2FPT0WU
LOUCY MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml61TWM2OD1yLkK5N{BvVQ>? NVLlXoRrW0GQR1XS
BB65-RCC NIHaRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\pNYhKSzVyPUCuN|A1KG6P NE\afZhUSU6JRWK=
D-542MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIiwcGxKSzVyPUCuN|I6KG6P MlS5V2FPT0WU
ONS-76 NYnycHNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DVNGlEPTB;MD6zN{BvVQ>? NG\WenhUSU6JRWK=
BB30-HNC NYL6SFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPMTWM2OD1yLkOzOUBvVQ>? M4\udHNCVkeHUh?=
KS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\ObWxCUUN3ME2wMlM1KG6P M4nsZ3NCVkeHUh?=
A388 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF60PYRKSzVyPUCuN|U3KG6P MorGV2FPT0WU
ES8 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TkXGlEPTB;MD60JI5O MkPoV2FPT0WU
MZ2-MEL NFi2bVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;HTWM2OD1yLkSwO{BvVQ>? M2raSHNCVkeHUh?=
HCC2998 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXvTWM2OD1yLkSxNkBvVQ>? MXXTRW5ITVJ?
D-247MG NWPsV4J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm4dHRKSzVyPUCuOFE{KG6P MXLTRW5ITVJ?
ACN Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDMVXlyUUN3ME2wMlQyPyCwTR?= MoHYV2FPT0WU
LB2518-MEL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLBTWM2OD1yLkSyOUBvVQ>? M{O4T3NCVkeHUh?=
ES1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDjTWM2OD1yLkSzJI5O M32we3NCVkeHUh?=
HCE-T M4myTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTGV3pKSzVyPUCuOFM6KG6P MV3TRW5ITVJ?
OS-RC-2 NHXPXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmyNFRKSzVyPUCuOFQhdk1? M1rwO3NCVkeHUh?=
MFH-ino MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XYSmlEPTB;MD60OFMhdk1? NV;KUpR4W0GQR1XS
OCUB-M MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XjZ2lEPTB;MD60OFchdk1? M13rRXNCVkeHUh?=
CP66-MEL MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPOGdKSzVyPUCuOFc{KG6P NVHWbXVuW0GQR1XS
LB771-HNC NH22bopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf0XlJKSzVyPUCuOFc1KG6P NEDFSVZUSU6JRWK=
DSH1 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonYTWM2OD1yLkS4JI5O NUKwN4ZiW0GQR1XS
HUTU-80 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwNUOzJI5O NILD[4ZUSU6JRWK=
CESS NF7PbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HwbmlEPTB;MD61N|ghdk1? M3vSenNCVkeHUh?=
NCI-H747 M2fzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;XTWM2OD1yLkWzPUBvVQ>? MWTTRW5ITVJ?
HT-144 M1X1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwNUe2JI5O M{T6RnNCVkeHUh?=
COLO-829 M13HT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkntTWM2OD1yLk[xOEBvVQ>? MU\TRW5ITVJ?
A4-Fuk NYTnR2JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq1U5BWUUN3ME2wMlYzOyCwTR?= NVryUJR2W0GQR1XS
GI-ME-N NVLIbmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\5c2lEPTB;MD62N|Qhdk1? NGTIfmpUSU6JRWK=
LB831-BLC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHnXWNKSzVyPUCuOlQyKG6P NYTqcWVbW0GQR1XS
HOP-62 NIL4XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNkS3JI5O M{jrcnNCVkeHUh?=
BB49-HNC NF3seGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNkWyJI5O NI\FW2lUSU6JRWK=
D-336MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3RblhKSzVyPUCuOlU4KG6P NV\m[lAzW0GQR1XS
TK10 NEXOSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLKdok2UUN3ME2wMlY4QSCwTR?= MlXKV2FPT0WU
Ramos-2G6-4C10 M3rWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nBS2lEPTB;MD62PVMhdk1? MX\TRW5ITVJ?
LB373-MEL-D M2q2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwNzDuUS=> MXfTRW5ITVJ?
SF126 M{DiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7FcFBKSzVyPUCuO|AyKG6P NGDxcWNUSU6JRWK=
UACC-257 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M164e2lEPTB;MD63NUBvVQ>? MYDTRW5ITVJ?
KINGS-1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwN{KyJI5O NIToVZdUSU6JRWK=
LS-513 NFv5eIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqye45qUUN3ME2wMlc{QSCwTR?= MnXUV2FPT0WU
GI-1 M1TUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTRS4NKSzVyPUCuO|Y1KG6P M3;ie3NCVkeHUh?=
ES7 NHLBeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInyWm1KSzVyPUCuO|Y3KG6P NIexV2tUSU6JRWK=
LB2241-RCC NUS1cZMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLR5VKSzVyPUCuPFA1KG6P NXjyZ2J3W0GQR1XS
D-263MG NVm3WVZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M362fWlEPTB;MD64NFchdk1? MVHTRW5ITVJ?
SW684 NWDQeFF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrKb5A5UUN3ME2wMlgzOSCwTR?= MUPTRW5ITVJ?
ML-2 NVzxOpkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGxTWM2OD1yLkiyNUBvVQ>? NF7XNYVUSU6JRWK=
SK-LMS-1 NE\NSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\GSHdKSzVyPUCuPFU1KG6P Mn7xV2FPT0WU
TE-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;MUWlEPTB;MD64OlUhdk1? NUPvXVJSW0GQR1XS
QIMR-WIL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;EeGpKSzVyPUCuPFg6KG6P MUPTRW5ITVJ?
NCI-H1355 M3[1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX2TWM2OD1yLki5OUBvVQ>? NYHWfWlOW0GQR1XS
SNB75 NX3weXV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrTWmdKSzVyPUCuPVEzKG6P NWLMPIhjW0GQR1XS
RXF393 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvlTWM2OD1yLkmxOEBvVQ>? NE[ycoFUSU6JRWK=
IST-MEL1 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTZem5KSzVyPUCuPVE4KG6P NFH3RpJUSU6JRWK=
SF268 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\KbY5KSzVyPUCuPVI{KG6P NYSwT3loW0GQR1XS
KALS-1 NHy4bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LiPWlEPTB;MD65NlUhdk1? MlfoV2FPT0WU
HC-1 M1\WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCwNVluUUN3ME2wMlk4PSCwTR?= NYHCcXd6W0GQR1XS
SW872 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDNTWM2OD1yLkm5OkBvVQ>? NIrFfJlUSU6JRWK=
PSN1 MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK5TGZKSzVyPUGuNFEhdk1? NInhXZhUSU6JRWK=
TE-1 NVXWVHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfDRYpKSzVyPUGuNFMhdk1? NUe4fGFoW0GQR1XS
TE-10 MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXZdHNzUUN3ME2xMlA{KG6P MV\TRW5ITVJ?
RKO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi3RW9TUUN3ME2xMlA3KG6P Mm[yV2FPT0WU
LC-2-ad NY\hWm1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqxTWM2OD1zLkC4JI5O M2PGXnNCVkeHUh?=
SK-MM-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\lcJdpUUN3ME2xMlA6KG6P NIDWbY5USU6JRWK=
VA-ES-BJ M3r6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTjPJlKSzVyPUGuNFkhdk1? NFHvVlZUSU6JRWK=
MZ7-mel MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLrTWM2OD1zLkC5JI5O NELqSZpUSU6JRWK=
D-392MG MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwMTDuUS=> MXHTRW5ITVJ?
CCRF-CEM NW[1RmluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwMUOgcm0> MkXSV2FPT0WU
EM-2 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jJOWlEPTB;MT6xOkBvVQ>? NV7tUJN5W0GQR1XS
HAL-01 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\FbIVKSzVyPUGuNVghdk1? MlTuV2FPT0WU
TE-8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnnPW5RUUN3ME2xMlE6KG6P NFHQS41USU6JRWK=
NCI-H1882 M2HNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWwTWM2OD1zLkKgcm0> M36z[XNCVkeHUh?=
Daudi NGX6PYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTlWHpKSzVyPUGuNlIhdk1? NWH3U41XW0GQR1XS
BL-41 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L2R2lEPTB;MT6yOUBvVQ>? M2PzOXNCVkeHUh?=
SR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXBPFhKSzVyPUGuNlUhdk1? NXTXWJZZW0GQR1XS
KM12 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwMkegcm0> NFPySJRUSU6JRWK=
K5 NGjqfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjkZ3ZKSzVyPUGuNlghdk1? M13u[nNCVkeHUh?=
A3-KAW M4K4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwMkigcm0> M4LLc3NCVkeHUh?=
CMK NXTYcoFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwMkmgcm0> NULhVZhDW0GQR1XS
Calu-6 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwMkmgcm0> M3fVeXNCVkeHUh?=
IST-SL2 NHLYPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\DSm5KSzVyPUGuN|Ehdk1? M2HxcHNCVkeHUh?=
OPM-2 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4juNmlEPTB;MT6zN{BvVQ>? MlzWV2FPT0WU
DU-4475 M17UbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDtVXhRUUN3ME2xMlM3KG6P NXP1SmVOW0GQR1XS
ECC12 M2nuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknDTWM2OD1zLkO3JI5O M3[0cnNCVkeHUh?=
L-540 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwM{egcm0> NVmyXHk4W0GQR1XS
CAS-1 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQOWlEPTB;MT6zO{BvVQ>? NFj5OJlUSU6JRWK=
PF-382 NVuwPZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDpZ4IzUUN3ME2xMlQ4KG6P M3TkXXNCVkeHUh?=
LS-411N MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rMU2lEPTB;MT61N{BvVQ>? NYfHTXZPW0GQR1XS
NCI-H69 M2K3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TCbmlEPTB;MT61OEBvVQ>? NUi1PIhjW0GQR1XS
NB12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPBOoNKSzVyPUGuOVYhdk1? NF3YO2xUSU6JRWK=
HEL NI\W[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwNkGgcm0> NYraSJdiW0GQR1XS
GCIY MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGyOXRIUUN3ME2xMlYzKG6P MlyzV2FPT0WU
EHEB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DxZ2lEPTB;MT62O{BvVQ>? NX3CZ4pJW0GQR1XS
TGBC1TKB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r0OmlEPTB;MT63NUBvVQ>? M4PPNHNCVkeHUh?=
KURAMOCHI NVj2fndwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\qdnlKSzVyPUGuO|Ihdk1? Ml[5V2FPT0WU
U-266 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPwTWM2OD1zLke2JI5O NUnmVVNOW0GQR1XS
LC4-1 M4\Pe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwN{mgcm0> MVHTRW5ITVJ?
NCI-H2126 NYrNNJBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j2UGlEPTB;MT64JI5O M37HeXNCVkeHUh?=
NCI-H1092 NWrlTWFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXoc2NKSzVyPUGuPEBvVQ>? MVXTRW5ITVJ?
GB-1 M2DZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\3TWM2OD1zLkixJI5O NV21TFRTW0GQR1XS
MV-4-11 NFTVPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwOEKgcm0> M36xPXNCVkeHUh?=
Becker MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT4enZ{UUN3ME2xMlg{KG6P MknVV2FPT0WU
MPP-89 NUHuWYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDTOnhKSzVyPUGuPFkhdk1? MWXTRW5ITVJ?
BE-13 NWfQZldOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke0TWM2OD1zLkmzJI5O Mn2zV2FPT0WU
697 M3SyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\HdFdKSzVyPUGuPVkhdk1? M{LCSXNCVkeHUh?=
NKM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJibl2= M4n0N3NCVkeHUh?=
NB13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HPTWlEPTB;MjDuUS=> M1LOdnNCVkeHUh?=
LS-123 NU\iWVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPIbIhTUUN3ME2yMlAzKG6P MWrTRW5ITVJ?
NB17 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTNTWM2OD1{LkC0JI5O M4nqWnNCVkeHUh?=
LAN-6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5SWlEPTB;Mj6wOUBvVQ>? MUfTRW5ITVJ?
EW-24 NYrxcZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwMEigcm0> NIf0NXdUSU6JRWK=
NOS-1 M3XiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzaTWM2OD1{LkGxJI5O M2HsNXNCVkeHUh?=
BL-70 M1u5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7UbpBRUUN3ME2yMlEzKG6P MVLTRW5ITVJ?
GT3TKB M{XXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DrRWlEPTB;Mj6xNkBvVQ>? Mn:wV2FPT0WU
HH MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwMUOgcm0> NV3qOphyW0GQR1XS
KE-37 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DBdWlEPTB;Mj6xN{BvVQ>? MVPTRW5ITVJ?
MOLT-4 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwMUOgcm0> M1vX[HNCVkeHUh?=
EKVX MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnPPYpKSzVyPUKuNVQhdk1? NUXoUlhrW0GQR1XS
KGN MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CybGlEPTB;Mj6xOUBvVQ>? MUHTRW5ITVJ?
ES4 M4Dte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe5dIVKSzVyPUKuNVYhdk1? M{nP[XNCVkeHUh?=
SJSA-1 NXnKW2dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwMkGgcm0> NXHZfoE4W0GQR1XS
KMOE-2 NFfRZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJwMkOgcm0> M2PVSHNCVkeHUh?=
NB5 NVX3fYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XFW2lEPTB;Mj6yO{BvVQ>? MXfTRW5ITVJ?
BC-1 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTl[m9KSzVyPUKuN|Ehdk1? M2i3XHNCVkeHUh?=
NB10 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHVTGdKSzVyPUKuN|Ihdk1? NGXLcXJUSU6JRWK=
RPMI-8226 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJwM{Wgcm0> NU\3dZJsW0GQR1XS
SCC-3 M{j3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLpc3VKSzVyPUKuN|chdk1? NWXNSFRZW0GQR1XS
ARH-77 NF;CNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GwOWlEPTB;Mj6zPEBvVQ>? MX7TRW5ITVJ?
NCI-H748 NHzlTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwM{mgcm0> NWLrdWs5W0GQR1XS
KU812 M2nPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH63UmdKSzVyPUKuOFIhdk1? M4LvSnNCVkeHUh?=
NCI-H64 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwNESgcm0> M3T2eXNCVkeHUh?=
NB69 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr1TWM2OD1{LkS2JI5O NYf4O2JKW0GQR1XS
KNS-81-FD MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwNEigcm0> NYPldHhLW0GQR1XS
LB1047-RCC NVvaTVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLWe45KSzVyPUKuOVchdk1? M4\QPXNCVkeHUh?=
EB-3 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TPUGlEPTB;Mj62OkBvVQ>? MlvWV2FPT0WU
Mo-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXy4dHU1UUN3ME2yMlc1KG6P NVfRN3NtW0GQR1XS
EW-16 NIDYTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnLfpFSUUN3ME2yMlc2KG6P NUXJVVlvW0GQR1XS
CTV-1 M3y4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTFSZRuUUN3ME2yMlghdk1? NHP1[ZJUSU6JRWK=
ETK-1 M1jpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLOTWM2OD1{Lki0JI5O M2mwT3NCVkeHUh?=
C2BBe1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwOEmgcm0> NYjTVWdrW0GQR1XS
MOLT-16 NUHPSY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XtO2lEPTB;Mj64PUBvVQ>? NIH4XohUSU6JRWK=
SW954 NIKxfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ZTWM2OD1{Lkmgcm0> MmSyV2FPT0WU
HT NF7VZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwMEKgcm0> MoTSV2FPT0WU
KARPAS-299 NF2yZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTXTWM2OD1|LkC2JI5O NXHJdIxsW0GQR1XS
MONO-MAC-6 M4Pm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HWfWlEPTB;Mz6xJI5O MYTTRW5ITVJ?
CGTH-W-1 NVm1fXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvD[4hKSzVyPUOuNUBvVQ>? MUTTRW5ITVJ?
SK-PN-DW NUHMZ2xHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwMUSgcm0> MkHsV2FPT0WU
CW-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ruXGlEPTB;Mz6yNUBvVQ>? M1L0[XNCVkeHUh?=
SK-N-DZ NG\1Rm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHPWmZnUUN3ME2zMlI3KG6P NGKyclNUSU6JRWK=
NEC8 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPiXHRKSzVyPUOuN|Uhdk1? M4Hp[HNCVkeHUh?=
LB996-RCC M4K2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf5eZJ3UUN3ME2zMlQhdk1? MWPTRW5ITVJ?
DB NGOwcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNwNEGgcm0> MXjTRW5ITVJ?
TE-15 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PNTGlEPTB;Mz60N{BvVQ>? Mk\QV2FPT0WU
COR-L88 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nC[GlEPTB;Mz60O{BvVQ>? MlTqV2FPT0WU
LAMA-84 M3zUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwNEmgcm0> NGO0NphUSU6JRWK=
MEG-01 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHEblBKSzVyPUOuOFkhdk1? MnXWV2FPT0WU
LOXIMVI NIrZRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnCR25KSzVyPUOuOUBvVQ>? M1HQV3NCVkeHUh?=
RPMI-8402 NHWx[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\FSWlEPTB;Mz61JI5O M{HaeHNCVkeHUh?=
KARPAS-45 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvLNZVNUUN3ME2zMlU1KG6P NY[1N5N5W0GQR1XS
HCC1187 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInnWXFKSzVyPUOuOVQhdk1? NYrY[lM4W0GQR1XS
MZ1-PC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O5c2lEPTB;Mz61OEBvVQ>? NETob2JUSU6JRWK=
no-11 NWTRUJpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwNUWgcm0> NYnJe5R2W0GQR1XS
EVSA-T MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGxTWM2OD1|Lk[gcm0> NWLxPGRlW0GQR1XS
DJM-1 M3q3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrNTWM2OD1|Lk[zJI5O NX;lWpVTW0GQR1XS
COLO-684 NH3VbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrtb4ZKSzVyPUOuOlYhdk1? NH3pZWFUSU6JRWK=
NMC-G1 M{Lk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnuSXhKSzVyPUOuOlghdk1? MoO4V2FPT0WU
LC-1F MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTNwN{Sgcm0> M3y4R3NCVkeHUh?=
RL95-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHkdoNKSzVyPUOuO|khdk1? NIryTpBUSU6JRWK=
COLO-320-HSR NXXwO2RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwOUKgcm0> MmrQV2FPT0WU
RCC10RGB MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7Z[JlbUUN3ME2zMlk{KG6P NF\OT2tUSU6JRWK=
HD-MY-Z NULmW4YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP1OoVKSzVyPUOuPVMhdk1? MU\TRW5ITVJ?
NCI-H2141 M2\QTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnme5FUUUN3ME20MlA2KG6P MmDsV2FPT0WU
K-562 NWTBSG1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nvSWlEPTB;ND6xNkBvVQ>? NUm5enBpW0GQR1XS
NCI-H1648 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjW[VFbUUN3ME20MlE{KG6P NG\F[2dUSU6JRWK=
OMC-1 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvUTWM2OD12LkG4JI5O NVi3VZA3W0GQR1XS
LB647-SCLC M1WxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\STWM2OD12LkKyJI5O NH\kSYVUSU6JRWK=
TE-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jUfmlEPTB;ND6yOUBvVQ>? MnLvV2FPT0WU
NOMO-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33p[mlEPTB;ND6zN{BvVQ>? Mm\PV2FPT0WU
Raji NFvRemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDTTWM2OD12LkS2JI5O MnvMV2FPT0WU
NALM-6 M3rB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[3NIVKSzVyPUSuOFkhdk1? M3z4S3NCVkeHUh?=
HL-60 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvhTI8xUUN3ME20MlY4KG6P M3rSenNCVkeHUh?=
IST-SL1 M4P3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvq[HdRUUN3ME20MlY5KG6P NYfsRWFYW0GQR1XS
MHH-PREB-1 NWfxeJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i2dmlEPTB;ND64OkBvVQ>? MnrRV2FPT0WU
MHH-NB-11 NGiyflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7sTWM2OD12LkmxJI5O NX\XOWVTW0GQR1XS
JiyoyeP-2003 NHnzUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITITHJKSzVyPUWgcm0> MkfWV2FPT0WU
SBC-1 M1j2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7EbGpKSzVyPUWuNFEhdk1? NU\5UVBKW0GQR1XS
CHP-126 NF7NbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq4TIh2UUN3ME21MlA3KG6P MV\TRW5ITVJ?
LU-139 NVGzOZZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\peZR2UUN3ME21MlE{KG6P MofXV2FPT0WU
NCI-SNU-5 M2f4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTVwMUegcm0> NIfqbItUSU6JRWK=
SW962 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTVwMkGgcm0> NFO2NWZUSU6JRWK=
EW-1 NVLNb5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL1b4VKSzVyPUWuN|Ehdk1? MYDTRW5ITVJ?
NCI-H1417 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX1Nm5KSzVyPUWuOVEhdk1? NEXPOmFUSU6JRWK=
LU-65 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDhbm0{UUN3ME21Mlg1KG6P NGXaWXZUSU6JRWK=
D-502MG Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSzc5NKSzVyPU[uN|chdk1? NYrndlQ6W0GQR1XS
BC-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LBbmlEPTB;Nj62NUBvVQ>? MlnZV2FPT0WU
GDM-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK3TWM2OD14Lke3JI5O NXu3SJFCW0GQR1XS
NCI-H2196 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoiyTWM2OD14Lkigcm0> M{O1cnNCVkeHUh?=
NB1 NHnLZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T5XWlEPTB;Nj64PEBvVQ>? NGHEUGhUSU6JRWK=
NCI-H345 M1jMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTdwMjDuUS=> NF\tSZJUSU6JRWK=
SU-DHL-1 NVLCdplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH6TWM2OD15LkK0JI5O Mn\yV2FPT0WU
JVM-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTYUFlbUUN3ME23MlI5KG6P M1KyT3NCVkeHUh?=
LU-134-A MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe3RVdkUUN3ME23MlM6KG6P MUnTRW5ITVJ?
NCI-H1694 M1XMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTdwNUigcm0> MVnTRW5ITVJ?
NCI-SNU-16 NYPxelh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnYUXBPUUN3ME23MlY2KG6P M2nsPXNCVkeHUh?=
L-363 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jlRWlEPTB;Nz63JI5O M2rzbHNCVkeHUh?=
KG-1 NFLUSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjkU2pKSzVyPUeuPVQhdk1? NGXXPZpUSU6JRWK=
MN-60 M{nUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DzV2lEPTB;OD6xOEBvVQ>? M2nLbnNCVkeHUh?=
NB6 NH;nb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7wW|BKSzVyPUiuOFghdk1? MkDnV2FPT0WU
MLMA M3LKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\BSFhKSzVyPUiuPFUhdk1? NHTMOlNUSU6JRWK=
ATN-1 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRThwOEmgcm0> M{T2Z3NCVkeHUh?=
SK-NEP-1 NXjPeppWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfiTWM2OD17LkCxJI5O NF;MVJJUSU6JRWK=
DMS-114 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfjTWM2OD17Lk[yJI5O NEf4RW9USU6JRWK=
CTB-1 NGXPWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES3cY5KSzVyPUmuOlchdk1? NV7IblV5W0GQR1XS
NCI-H2081 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj2Voh1UUN3ME2xNE4xQSCwTR?= NVzoTmU5W0GQR1XS
ES5 NH3HZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GzVGlEPTB;MUCuN|ghdk1? NETKTm9USU6JRWK=
HCC1599 NYHlTWk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHKXVdKSzVyPUGxMlkyKG6P NFLaT|VUSU6JRWK=
NCI-H23 M1jEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF{LkGyJI5O MmeyV2FPT0WU
NCI-H1581 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6zXoxiUUN3ME2xNk4zQCCwTR?= MYfTRW5ITVJ?
JVM-3 NG\hUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDETWM2OD1zMj65PUBvVQ>? M2jjSHNCVkeHUh?=
NCI-SNU-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF|LkG5JI5O MkD3V2FPT0WU
NB7 NX;RZVB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT6OVNQUUN3ME2xOU46OiCwTR?= MWjTRW5ITVJ?
JAR NEK2eHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDCVYg1UUN3ME2xOk4yOyCwTR?= NVzVfJNVW0GQR1XS
TGW M1;FW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKd3BKSzVyPUG2MlQ5KG6P M13U[HNCVkeHUh?=
U-87-MG NE[wSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvGTWM2OD1zNj63OkBvVQ>? NWT4bXB{W0GQR1XS
NCI-H1436 NWS2[ZN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPCNVJKSzVyPUG3MlAyKG6P MV;TRW5ITVJ?
GOTO MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3UcWJ5UUN3ME2xO{4xPiCwTR?= M{DBUnNCVkeHUh?=
COLO-800 NX3xO|ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXoTWM2OD1zNz62OEBvVQ>? Mm\OV2FPT0WU
MFM-223 M3Xa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF5LkmxJI5O MoDpV2FPT0WU
EW-18 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm5PXBKSzVyPUG3Mlk3KG6P Mo\qV2FPT0WU
NB14 NXK4TWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPTZnZKSzVyPUG3Mlk5KG6P MXjTRW5ITVJ?
EB2 NWHUcYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TtXmlEPTB;MUiuNFghdk1? NGHPPW5USU6JRWK=
EoL-1- NH;SPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\jTWM2OD1zOD6zNUBvVQ>? NUSxe3o1W0GQR1XS
NCCIT Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHWWoZnUUN3ME2xPE4{PiCwTR?= NH;DUFZUSU6JRWK=
DG-75 Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPvTWM2OD1zOD62NUBvVQ>? MkLuV2FPT0WU
HCC2218 NVLOUZZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\lTWM2OD1zOT61JI5O MWfTRW5ITVJ?
TE-6 NF3ZeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDMXYtKSzVyPUKwMlA5KG6P NIPEN2ZUSU6JRWK=
SF539 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJyLk[3JI5O M2[4d3NCVkeHUh?=
NCI-H446 M4DU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJzLkG4JI5O NYj0OWt6W0GQR1XS
IST-MES1 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q0bGlEPTB;MkKuO|chdk1? MULTRW5ITVJ?
NCI-H82 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz3TWM2OD1{Mz6wNkBvVQ>? M{GxTnNCVkeHUh?=
HCC2157 NHLqeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjnUWRHUUN3ME2yN{4yOyCwTR?= MkfFV2FPT0WU
EW-12 M4fZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ|LkG3JI5O NH3E[5RUSU6JRWK=
SIMA MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO3N3VKSzVyPUKzMlM5KG6P MljnV2FPT0WU
DOHH-2 NELMR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[5OHBxUUN3ME2yN{41PSCwTR?= NGPwfpdUSU6JRWK=
IM-9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXwTWM2OD1{Mz61OEBvVQ>? NX;ORZh6W0GQR1XS
EC-GI-10 NX:4U3B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HSd2lEPTB;MkSuNlMhdk1? MX\TRW5ITVJ?
HDLM-2 M1[xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHTZYVKSzVyPUK0MlU1KG6P MnXKV2FPT0WU
LS-1034 NVzpW4w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ3Lke1JI5O M2PlS3NCVkeHUh?=
REH NX\OZ3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP3N3JKSzVyPUK2MlQyKG6P M4Hwc3NCVkeHUh?=
LU-165 M17tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXhOGxSUUN3ME2yOk44OiCwTR?= M1;xeXNCVkeHUh?=
NH-12 NGnRSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PIb2lEPTB;MkeuOlchdk1? MYDTRW5ITVJ?
WSU-NHL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHIdItKSzVyPUK4MlM6KG6P NIDSVVdUSU6JRWK=
ECC4 M{SwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\zbGlEPTB;MkiuO|khdk1? NGDTXY9USU6JRWK=
OCI-AML2 NYHkZ3plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHpTHJIUUN3ME2yPU43QSCwTR?= MlXDV2FPT0WU
EW-3 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrQNmJNUUN3ME2zNE42QSCwTR?= NHnpNpRUSU6JRWK=
NCI-H526 M2rHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXQ[pRKUUN3ME2zNk42PCCwTR?= MnPDV2FPT0WU
NCI-H719 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTYUFNKSzVyPUO0MlMyKG6P MkfIV2FPT0WU
KARPAS-422 NVXHVndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN3LkC0JI5O MVnTRW5ITVJ?
SK-MEL-1 M3u4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;xSGNKSzVyPUO1MlE4KG6P NW[2U3A6W0GQR1XS
ES3 MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDqTWM2OD1|NT6xPUBvVQ>? MWfTRW5ITVJ?
UACC-812 NH6w[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHzOXlKSzVyPUO1MlQ1KG6P NETQ[G5USU6JRWK=
C8166 M2[wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN3Lkegcm0> NXnCRYsyW0GQR1XS
MDA-MB-134-VI NWT0V|JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN3Lki3JI5O M4e2cHNCVkeHUh?=
D-283MED M17sUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rLPGlEPTB;M{euO|khdk1? NVXQe|M5W0GQR1XS
SHP-77 NFHEfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rMUmlEPTB;M{iuNFMhdk1? M1rPZnNCVkeHUh?=
NCI-H2227 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm4TWM2OD12MD60PUBvVQ>? M3;hO3NCVkeHUh?=
SKM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rOVWlEPTB;NEKuOlMhdk1? M2PEenNCVkeHUh?=
L-428 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjrd3AyUUN3ME20N{45PiCwTR?= MXvTRW5ITVJ?
RPMI-6666 M2L0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV65Z|ZbUUN3ME20OU45QSCwTR?= MoXxV2FPT0WU
NCI-H716 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLGU2JKSzVyPUS4MlgyKG6P MkO2V2FPT0WU
DMS-79 M1XxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX62W2VnUUN3ME21NE44OSCwTR?= NVzTXZNDW0GQR1XS
RS4-11 NEnRSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTVyLki4JI5O NGPjVWZUSU6JRWK=
NCI-H720 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPifWxKSzVyPUWxMlEyKG6P NHXDZWVUSU6JRWK=
MC-CAR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HK[GlEPTB;NUGuOVIhdk1? NY[5Om5WW0GQR1XS
TALL-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHNcGRKSzVyPUWzMlkyKG6P MnLjV2FPT0WU
NCI-N87 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf5PI9UUUN3ME21OE4yQCCwTR?= MXPTRW5ITVJ?
P30-OHK M1Gxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LGVWlEPTB;NUSuOlEhdk1? Ml\LV2FPT0WU
LP-1 NGfKVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rLPGlEPTB;NkGuNlghdk1? M4LXbHNCVkeHUh?=
YT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT4T29zUUN3ME22NU45KG6P M4SyVXNCVkeHUh?=
MRK-nu-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrwRYtKSzVyPU[xMlgzKG6P NIrLeoZUSU6JRWK=
BT-474 NHHlWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljWTWM2OD14NTDuUS=> NWfJXoQ1W0GQR1XS
NCI-H322M NV32ZZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZ4LkGxJI5O Mlv6V2FPT0WU
NCI-H128 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DFSmlEPTB;N{SuO|chdk1? MXXTRW5ITVJ?
KMS-12-PE NUPJdXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWwTWM2OD15Nj6yOEBvVQ>? MXjTRW5ITVJ?
KP-N-YS MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTd4Lke0JI5O Mo\qV2FPT0WU
ALL-PO MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLTTWM2OD15Nz62OkBvVQ>? Mm\OV2FPT0WU
EW-13 NVe3WWljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HmZ2lEPTB;N{euO|Yhdk1? MnvGV2FPT0WU
EW-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHRd3VXUUN3ME23PE42OiCwTR?= MWHTRW5ITVJ?
SK-N-FI MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRThyLkKgcm0> MkfvV2FPT0WU
CAL-148 M3XMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzwUpJHUUN3ME24NU45PCCwTR?= MoezV2FPT0WU
RL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lue2lEPTB;OE[uNFkhdk1? MX3TRW5ITVJ?
AM-38 NVu2R3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvUSFZnUUN3ME24PE4xQCCwTR?= MmHnV2FPT0WU
RH-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\mepJKSzVyPUm5Mlg2KG6P MV;TRW5ITVJ?
NCI-H1770 NXPxe4hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;iNFFKSzVyPUGwNk41QSCwTR?= MUjTRW5ITVJ?
SIG-M5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrvTWM2OD1zMEWuNFYhdk1? M1rBRXNCVkeHUh?=
GR-ST M1qye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr1fldKSzVyPUGxN{4{PCCwTR?= MmHxV2FPT0WU
ST486 NV\wfo1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjFNGtIUUN3ME2xNVQvODZibl2= M{PE[HNCVkeHUh?=
NCI-H1650 NY[xSlF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHCTWM2OD1zMUWuNlkhdk1? NFfZOHVUSU6JRWK=
MHH-CALL-2 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\nbpRbUUN3ME2xNVUvPyCwTR?= NHfWe2ZUSU6JRWK=
BV-173 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF{Mj63NUBvVQ>? NHvsRlVUSU6JRWK=
MC116 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF2OD64OUBvVQ>? MYHTRW5ITVJ?
NCI-H524 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfBVmtEUUN3ME2xOVkvOSCwTR?= NY\KPYFWW0GQR1XS
SCLC-21H MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\FfFVHUUN3ME2xOVkvPDFibl2= NXS3NFFlW0GQR1XS
NCI-H1304 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjidYtKSzVyPUG2PU4zOSCwTR?= NUXKbW9LW0GQR1XS
NCI-H510A M3vXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHk[VNKSzVyPUG4OU4{PyCwTR?= NYXIdFB5W0GQR1XS
NCI-H209 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfLW|RKSzVyPUG5Ok42OiCwTR?= NY\KWHRwW0GQR1XS
KM-H2 M4jmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrPRVBKSzVyPUG5O{4xPSCwTR?= MWHTRW5ITVJ?
NCI-H1395 M3TuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7jU5BKSzVyPUKxNE4yOyCwTR?= M3LSTHNCVkeHUh?=
NCI-H1155 M174Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHznUWJKSzVyPUKzNE4{OiCwTR?= NHPVZ5ZUSU6JRWK=
COR-L279 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXQTWM2OD1{NUKuNVchdk1? MoK1V2FPT0WU
NCI-H1299 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ4MT63NUBvVQ>? MnrPV2FPT0WU
EW-22 NHTi[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nITGlEPTB;Mk[zMlc2KG6P MXvTRW5ITVJ?
SK-MEL-2 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHFTWM2OD1{OEGuPUBvVQ>? M2nBWXNCVkeHUh?=
KASUMI-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DZUWlEPTB;MkizMlA2KG6P NH3q[ZlUSU6JRWK=
NCI-H187 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnkTHRJUUN3ME2yPFcvODhibl2= NH\5OZhUSU6JRWK=
NCI-H2171 NVHX[ZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6yTWM2OD1{OEiuPVIhdk1? NH\QS4VUSU6JRWK=
LNCaP-Clone-FGC NH\DZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XZSWlEPTB;Mkm1MlI3KG6P NHPDfphUSU6JRWK=
NCI-H1522 M{TRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TBUGlEPTB;M{C3MlA2KG6P MVHTRW5ITVJ?
SCH NX[wclBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j2TGlEPTB;M{KyMlIzKG6P MXnTRW5ITVJ?
THP-1 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHidndJUUN3ME2zNlIvPiCwTR?= MoDuV2FPT0WU
SNU-C1 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f4ZWlEPTB;M{[yMlA6KG6P NYnvb49OW0GQR1XS
CA46 NISw[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXWOFRKSzVyPUO3N{43OyCwTR?= Mmi3V2FPT0WU
NCI-H1963 NH7EfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXTXllKSzVyPUO4Ok4yQSCwTR?= MXXTRW5ITVJ?
DEL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN7MT6yO{BvVQ>? MV3TRW5ITVJ?
TUR NVLaS5h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrIb|JKSzVyPUO5Ok43OSCwTR?= NY\jbJliW0GQR1XS
NCI-H226 NX32OJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRyMz6yN{BvVQ>? M1XKOnNCVkeHUh?=
COLO-668 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi0TpZqUUN3ME20NFMvPTdibl2= MmTMV2FPT0WU
CPC-N M2LINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRyMz63O{BvVQ>? M4HwO3NCVkeHUh?=
NCI-H889 NVe5[4NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoflTWM2OD12NkGuPVIhdk1? MUnTRW5ITVJ?
J-RT3-T3-5 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\0ZVVKSzVyPUWzNk42PyCwTR?= NEnGdlNUSU6JRWK=
MSTO-211H Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnriTWM2OD13N{SuNlYhdk1? NHzET4hUSU6JRWK=
SCC-15 MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV65NJhzUUN3ME22OlcvPDdibl2= MUHTRW5ITVJ?
SUP-T1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXFRmZKSzVyPU[4Ok4xPCCwTR?= MnjTV2FPT0WU
DMS-153 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILqfnpKSzVyPUe0Ok45OyCwTR?= MnjVV2FPT0WU
MS-1 M{HXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jnWGlEPTB;N{W5MlQzKG6P M{XqN3NCVkeHUh?=
TC-YIK NUnxRm9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrtNnRKSzVyPUe4NU4xOSCwTR?= NX\wcJVJW0GQR1XS
RPMI-8866 NIjMVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFyME[uNlgh|ryP MWjTRW5ITVJ?
KY821 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfCco1KSzVyPUGwN|YvODRizszN MWnTRW5ITVJ?
P31-FUJ NIXVZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmixTWM2OD1zMUGyMlc2KM7:TR?= M{iwdXNCVkeHUh?=
COLO-824 NUf2UWl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PHSWlEPTB;MUK2NU44QCEQvF2= M1zB[XNCVkeHUh?=
U-698-M NWXNclVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPER|FKSzVyPUKyOlIvOTVizszN M3vl[XNCVkeHUh?=
TE-441-T NXrLR3plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPtTpR7UUN3ME2yOVIyNjdizszN MkXxV2FPT0WU
IMR-5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN2MEmuOlIh|ryP MkO2V2FPT0WU
NCI-H1838 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLFTWM2OD12MUi2MlMzKM7:TR?= Mlm2V2FPT0WU

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[4]

+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験:

[5]

+ 展開
  • 細胞株: Human multiple myeloma cells line U266
  • 濃度: ~10 μM
  • 反応時間: 2 days
  • 実験の流れ:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Human plasmacytoma xenografts RPMI 8226
  • 製剤: Saline
  • 投薬量: 1 mg/kg
  • 投与方法: i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4

CAS No. 179324-69-7
保管
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome信号経路図

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID